Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study.

Hortobagyi GN, Bodey GP, Buzdar AU, Frye D, Legha SS, Malik R, Smith TL, Blumenschein GR, Yap HY, Rodriguez V.

J Clin Oncol. 1987 Mar;5(3):354-64.

PMID:
3819804
3.

High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study.

Hortobagyi GN, Buzdar AU, Bodey GP, Kau S, Rodriguez V, Legha SS, Yap HY, Blumenschein GR.

J Clin Oncol. 1987 Feb;5(2):178-84.

PMID:
3543241
4.

Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.

Calabresi F, Di Lauro L, Marolla P, Curcio CG, Paoletti G, Calabró A, Giannarelli D, Ballatore P, Foggi CM, Di Palma M, et al.

Semin Oncol. 1991 Apr;18(2 Suppl 4):66-72.

PMID:
2031201
5.

A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.

Bennett JM, Muss HB, Doroshow JH, Wolff S, Krementz ET, Cartwright K, Dukart G, Reisman A, Schoch I.

J Clin Oncol. 1988 Oct;6(10):1611-20.

PMID:
3049953
7.

Tandem autotransplantation for the treatment of metastatic breast cancer.

Broun ER, Sridhara R, Sledge GW, Loesch D, Kneebone PH, Hanna M, Hromas R, Cornetta K, Einhorn LH.

J Clin Oncol. 1995 Aug;13(8):2050-5.

PMID:
7636548
8.

A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.

Alonso MC, Tabernero JM, Ojeda B, Llanos M, Solà C, Climent MA, Seguí MA, López JJ.

Breast Cancer Res Treat. 1995 Apr;34(1):15-24.

PMID:
7749156
9.

Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.

Bontenbal M, Creemers GJ, Braun HJ, de Boer AC, Janssen JT, Leys RB, Ruit JB, Goey SH, van der Velden PC, Kerkhofs LG, Schothorst KL, Schmitz PI, Bokma HJ, Verweij J, Seynaeve C; Dutch Community Setting Trial for the Clinical Trial Group.

J Clin Oncol. 2005 Oct 1;23(28):7081-8.

PMID:
16192591
11.

Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results.

Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN.

Oncologist. 2011;16(11):1527-34. doi: 10.1634/theoncologist.2011-0134. Epub 2011 Oct 31.

12.

Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate.

Aboud A, Buzdar AU, Yap HY, Hortobagyi GN, Blumenschein GR.

J Surg Oncol. 1984 Jul;26(3):205-7.

PMID:
6610802
13.

5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer.

Lopez M, Papaldo P, Di Lauro L, Vici P, Carpano S, Conti EM.

Oncology. 1989;46(1):1-5.

PMID:
2915887
14.

5-Fluorouracil, adriamycin and cyclophosphamide combined with high-dose medroxyprogesterone acetate in advanced breast cancer.

Lopez M, Di Lauro L, Perno CF, Papaldo P, Barduagni M, Barduagni A.

Tumori. 1983 Dec 31;69(6):545-51.

PMID:
6229920
15.

Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control.

Albert JM, Buzdar AU, Guzman R, Allen PK, Strom EA, Perkins GH, Woodward WA, Hoffman KE, Tereffe W, Hunt KK, Buchholz TA, Oh JL.

Breast Cancer Res Treat. 2011 Jul;128(2):421-7. doi: 10.1007/s10549-011-1562-7. Epub 2011 May 8.

PMID:
21553292
16.

Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.

Jassem J, Pieńkowski T, Płuzańska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, Berzins J, Nagykalnai T, Wigler N, Renard J, Munier S, Weil C; Central & Eastern Europe and Israel Pacitaxel Breast Cancer Study Group.

J Clin Oncol. 2001 Mar 15;19(6):1707-15.

PMID:
11251000
17.

High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.

Morgan RJ Jr, Doroshow JH, Venkataraman K, Chang K, Raschko J, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V, Margolin K, Forman S, Akman S, Coluzzi P, Ahn C, Weiss L, Gadgil U, Harrison J.

Clin Cancer Res. 1997 Dec;3(12 Pt 1):2337-45.

18.

Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial.

Italian Multicentre Breast Study with Epirubicin, Ambrosini G, Balli M, Garusi G, Demicheli R, Jirillo A, Bonciarelli G, Bruscagnin G, Fila G, Bumma C, Lacroix F, Buzzi F, Di Costanzo F, Padalino D, Brugia M, Calabresi F, Natali M, Cartei G, Chiesa G, Blasina B, Ciambellotti E, Moro G, D'Aquino S, Altavilla G, Adamo V, De Maria D, Falchi AM, Bertoncelli P, Farris A, Fiorentino M, Fornasiero A, Fosser V, Daniele O, Foggi CM, Speranza GB, Sartori S, Camilluzzi E, Gallo L, Poggio R, Secondo V, Gambi A, Grignani F, Capodicasa E, Lopez M, Papaldo P, Di Lauro L, Vici P, Marenco G, Folco U, Bonanni F, Marsilio P, Palazzotto G, Di Carlo A, Cusimano MP, Pastorino G, Puccetti C, Giusto M, Rausa L, Gebbia N, Palmeri S, D'Alessandro N, Saccani F, Becchi G, Schieppati G, Spinelli I, Tagliagambe A, Tonato M, Minotti V, Ardia A, Viaro D, De Micheli P, Zingali G, Sacchetti G, Intini C.

J Clin Oncol. 1988 Jun;6(6):976-82.

PMID:
2897433
19.

Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.

Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN.

Clin Cancer Res. 2002 May;8(5):1073-9.

20.

A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma.

Blajman C, Balbiani L, Block J, Coppola F, Chacon R, Fein L, Bonicatto S, Alvarez A, Schmilovich A, Delgado FM.

Cancer. 1999 Mar 1;85(5):1091-7.

PMID:
10091793

Supplemental Content

Support Center